The introduction of IL-5 targeting treatment in neoplastic or idiopathic hypereosinophilia mirrors the increasing interest in recent years in mABs targeting the IL-5 pathway for the treatment of hypereosinophilic conditions such as severe asthma and EGPA (33, 153, 200). Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.